Over the past year, biotech giant Eli Lilly (NYSE: LLY) has been crushing the market. The company's performance has been so strong that some might think they have missed the boat and that it's too late to get in on this leading drugmaker. But that's not the case. Eli Lilly continues to give investors reasons why it might deliver outsize returns for at least the next half a decade, if not much longer.

Let's consider why the company's shares are a buy, even though they aren't far from their 52-week high. 

Continue reading

Source Fool.com